

RESEARCH ARTICLE

Morindone from *Morinda citrifolia* as a potential antiproliferative agent against colorectal cancer cell lines

Cheek Wui Chee¹, Nor Hisam Zamakshshari², Vannajan Sanghiran Lee^{3,4,5*}, Iskandar Abdullah^{3,4}, Rozana Othman^{4,6,7}, Yean Kee Lee^{3,4}, Najihah Mohd Hashim^{4,6,7*}, Nurshamimi Nor Rashid^{1,4,6*}

1 Department of Molecular Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia, **2** Department of Chemistry, Faculty of Resources Science, Universiti Malaysia Sarawak, Sarawak, Malaysia, **3** Department of Chemistry, Faculty of Science, Universiti Malaya, Kuala Lumpur, Malaysia, **4** Drug Design and Development Research Group, Universiti Malaya, Kuala Lumpur, Malaysia, **5** Centre of Theoretical and Computational Physics, Faculty of Science, Universiti Malaya, Kuala Lumpur, Malaysia, **6** Centre for Natural Products Research and Drug Discovery, Universiti Malaya, Kuala Lumpur, Malaysia, **7** Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia

* nurshamimi@um.edu.my (NNR); najihahmh@um.edu.my (NMH); vannajan@um.edu.my (VSL)



OPEN ACCESS

Citation: Chee CW, Zamakshshari NH, Lee VS, Abdullah I, Othman R, Lee YK, et al. (2022) Morindone from *Morinda citrifolia* as a potential antiproliferative agent against colorectal cancer cell lines. PLoS ONE 17(7): e0270970. <https://doi.org/10.1371/journal.pone.0270970>

Editor: Chakrabhavi Dhananjaya Mohan, University of Mysore, INDIA

Received: October 17, 2021

Accepted: June 21, 2022

Published: July 12, 2022

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0270970>

Copyright: © 2022 Chee et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its [Supporting Information](#) files.

Abstract

There is an increasing demand in developing new, effective, and affordable anti-cancer agents against colon and rectal. In this study, our aim is to identify the potential anthraquinone compounds from the root bark of *Morinda citrifolia* to be tested *in vitro* against colorectal cancer cell lines. Eight potential anthraquinone compounds were successfully isolated, purified and tested for both *in-silico* and *in-vitro* analyses. Based on the *in-silico* prediction, two anthraquinones, morindone and rubiadin, exhibit a comparable binding affinity towards multitargets of β -catenin, MDM2-p53 and KRAS. Subsequently, we constructed a 2D interaction analysis based on the above results and it suggests that the predicted anthraquinones from *Morinda citrifolia* offer an attractive starting point for potential antiproliferative agents against colorectal cancer. *In vitro* analyses further indicated that morindone and damnacanthol have significant cytotoxicity effect and selectivity activity against colorectal cancer cell lines.

Introduction

Colorectal cancer (CRC) as a malignant cancer affecting both male and female, is ranked the third most common cancer worldwide and second most frequent cancer in Malaysia [1]. Significant associations between dietary factors and CRC risk have been determined, in addition to smoking and alcohol intake [2]. Regular consumption of fruits and vegetables was demonstrated effective in reducing CRC risk as polyphenolic compounds in plants contribute to decreasing cell adhesion process, migration, and tumour angiogenesis [3]. Standard chemotherapy regimens in treating CRC patients accommodates the use of cancer drug particularly 5-fluorouracil (5-FU) and doxorubicin hydrochloride (DOX) that function by inhibiting DNA synthesis [4]. Despite higher survival rate in patients, the adverse toxicity risk associated with